Feng Pan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Feng Pan has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Si-Qi Qiu
Diagnosis and Treatment Center of Breast Diseases, Shantou Central Hospital, Shantou, China
2 shared publications Wen-Qi Shi
Clinical Research Center, Shantou Central Hospital, Shantou, China
2 shared publicationsBao-Hua Huang
Department of Pathology, Shantou Central Hospital, Shantou, China
1 shared publicationChun-Peng Liu
Department of Pathology, Shantou Central Hospital, Shantou, China
1 shared publicationChun-Yan Zhu
Department of Pathology, Shantou University Medical College, Shantou, China
1 shared publication- En-Min Li
Shantou University Medical College
1 shared publication
Latest Publications
- Open Access
Riboflavin Deficiency-Induced Angular Stomatitis and Conjunctivitis in Associated with Gut Microbiota Dysbiosis
Purpose: Riboflavin deficiency causes ariboflavinosis, and the purpose of this study is to investigate the potential biological factors underlying its occurrence. Methods: Male F344 rats were randomly assigned to R6 and R0 groups. The healthy controls (R6 group) was fed a riboflavin-normal diet (6 mg/kg riboflavin), while the R0 group was fed a riboflavin-deficient diet (0 mg/kg riboflavin) for 16 weeks. Following this period, the R0 group was switched to a riboflavin replenishment diet (6 mg/kg riboflavin) for an additional 4 weeks (weeks 17-20). The bacterial communities were analyzed using high-throughput 16S rRNA gene sequencing. Results: Riboflavin deficiency induces ariboflavinosis in rats (66.7%), characterized by angular stomatitis and conjunctivitis. With riboflavin replenishment, ariboflavinosis was completely resolved. Riboflavin deficiency altered the gut microbiota co-occurrence network and composition. The potential mechanism is predicted to involve an increase in glycan biosynthesis and metabolism within the gut microbiota, particularly in lipopolysaccharide biosynthesis pathways. Conclusions: These findings suggest that riboflavin deficiency induces ariboflavinosis by altering the gut microbiota, providing new insights into the mechanisms of riboflavin deficiency and its association with chronic inflammation. Clinical perspectives: Riboflavin is an essential nutrient that must be obtained through the diet, as the human body cannot synthesize it. Since riboflavin is not stored in the body, regular dietary intake is necessary. Riboflavin deficiency is prevalent worldwide and can lead to ariboflavinosis. However, the specific mechanisms underlying riboflavin deficiency-induced ariboflavinosis remain unclear. This study demonstrates that riboflavin deficiency causes ariboflavinosis (characterized by angular stomatitis and conjunctivitis) in rats and reveals a close relationship between riboflavin deficiency and alterations in gut microbiota composition. Gut dysbiosis appears to be a hallmark of ariboflavinosis and may serve as a promising diagnostic biomarker and therapeutic target for the condition.
Open AccessRiboflavin Deficiency-Induced Angular Stomatitis and Conjunctivitis in Associated with Gut Microbiota Dysbiosis
Purpose: Riboflavin deficiency causes ariboflavinosis, and the purpose of this study is to investigate the potential biological factors underlying its occurrence. Methods: Male F344 rats were randomly assigned to R6 and R0 groups. The healthy controls (R6 group) was fed a riboflavin-normal diet (6 mg/kg riboflavin), while the R0 group was fed a riboflavin-deficient diet (0 mg/kg riboflavin) for 16 weeks. Following this period, the R0 group was switched to a riboflavin replenishment diet (6 mg/kg riboflavin) for an additional 4 weeks (weeks 17-20). The bacterial communities were analyzed using high-throughput 16S rRNA gene sequencing. Results: Riboflavin deficiency induces ariboflavinosis in rats (66.7%), characterized by angular stomatitis and conjunctivitis. With riboflavin replenishment, ariboflavinosis was completely resolved. Riboflavin deficiency altered the gut microbiota co-occurrence network and composition. The potential mechanism is predicted to involve an increase in glycan biosynthesis and metabolism within the gut microbiota, particularly in lipopolysaccharide biosynthesis pathways. Conclusions: These findings suggest that riboflavin deficiency induces ariboflavinosis by altering the gut microbiota, providing new insights into the mechanisms of riboflavin deficiency and its association with chronic inflammation. Clinical perspectives: Riboflavin is an essential nutrient that must be obtained through the diet, as the human body cannot synthesize it. Since riboflavin is not stored in the body, regular dietary intake is necessary. Riboflavin deficiency is prevalent worldwide and can lead to ariboflavinosis. However, the specific mechanisms underlying riboflavin deficiency-induced ariboflavinosis remain unclear. This study demonstrates that riboflavin deficiency causes ariboflavinosis (characterized by angular stomatitis and conjunctivitis) in rats and reveals a close relationship between riboflavin deficiency and alterations in gut microbiota composition. Gut dysbiosis appears to be a hallmark of ariboflavinosis and may serve as a promising diagnostic biomarker and therapeutic target for the condition.
- Open Access
- 19 December 2024
- Published by Springer Nature in Communications Biology
- Vol. 7 (1) , 1-16
EZH2 elicits CD8+ T-cell desert in esophageal squamous cell carcinoma via suppressing CXCL9 and dendritic cells
CD8+ T cell spatial distribution in the context of tumor microenvironment (TME) dictates the immunophenotypes of tumors, comprised of immune-infiltrated, immune-excluded and immune-desert, discriminating “hot” from “cold” tumors. The infiltration of cytotoxic CD8+ T cells is associated with favorable therapeutic response. Hitherto, the immunophenotypes of esophageal squamous cell carcinoma (ESCC) have not yet been comprehensively delineated. Herein, we comprehensively characterized the immunophenotypes of ESCC and identified a subset of ESCC, which was defined as cold tumor and characterized with CD8+ T cell-desert TME. However, the mechanism underlying the defect of CD8+ T cells in TME is still pending. Herein, we uncovered that tumor cell-intrinsic EZH2 with high expression was associated with the immunophenotype of immune-desert tumors. Targeted tumor cell-intrinsic EZH2 rewired the transcriptional activation of CXCL9 mediated by NF-κB and concomitantly reinvigorated DC maturation differentiation via inducing the reduction of VEGFC secretion, thereby enhancing the infiltration of cytotoxic CD8+ T cells into TME and inhibiting tumor immune evasion. Our findings identify EZH2 as a potential therapeutic target and point to avenues for targeted therapy applied to patients with ESCC characterized by CD8+ T cell-desert tumors.
- 19 December 2024
- Published by Springer Nature in Communications Biology
- Vol. 7 (1) , 1-16
Open AccessEZH2 elicits CD8+ T-cell desert in esophageal squamous cell carcinoma via suppressing CXCL9 and dendritic cells
CD8+ T cell spatial distribution in the context of tumor microenvironment (TME) dictates the immunophenotypes of tumors, comprised of immune-infiltrated, immune-excluded and immune-desert, discriminating “hot” from “cold” tumors. The infiltration of cytotoxic CD8+ T cells is associated with favorable therapeutic response. Hitherto, the immunophenotypes of esophageal squamous cell carcinoma (ESCC) have not yet been comprehensively delineated. Herein, we comprehensively characterized the immunophenotypes of ESCC and identified a subset of ESCC, which was defined as cold tumor and characterized with CD8+ T cell-desert TME. However, the mechanism underlying the defect of CD8+ T cells in TME is still pending. Herein, we uncovered that tumor cell-intrinsic EZH2 with high expression was associated with the immunophenotype of immune-desert tumors. Targeted tumor cell-intrinsic EZH2 rewired the transcriptional activation of CXCL9 mediated by NF-κB and concomitantly reinvigorated DC maturation differentiation via inducing the reduction of VEGFC secretion, thereby enhancing the infiltration of cytotoxic CD8+ T cells into TME and inhibiting tumor immune evasion. Our findings identify EZH2 as a potential therapeutic target and point to avenues for targeted therapy applied to patients with ESCC characterized by CD8+ T cell-desert tumors.
- Open Access
- 10 September 2024
- Published by Springer Nature in Cancer Cell International
- Vol. 24 (1) , 1-13
Pan-cancer analysis reveals CCL5/CSF2 as potential predictive biomarkers for immune checkpoint inhibitors
Currently, there are no optimal biomarkers available for distinguishing patients who will respond to immune checkpoint inhibitors (ICIs) therapies. Consequently, the exploration of novel biomarkers that can predict responsiveness to ICIs is crucial in the field of immunotherapy. We estimated the proportions of 22 immune cell components in 10 cancer types (6,128 tumors) using the CIBERSORT algorithm, and further classified patients based on their tumor immune cell proportions in a pan-cancer setting using k-means clustering. Differentially expressed immune genes between the patient subgroups were identified, and potential predictive biomarkers for ICIs were explored. Finally, the predictive value of the identified biomarkers was verified in patients with urothelial carcinoma (UC) and esophageal squamous cell carcinoma (ESCC) who received ICIs. Our study identified two subgroups of patients with distinct immune infiltrating phenotypes and differing clinical outcomes. The patient subgroup with improved outcomes displayed tumors enriched with genes related to immune response regulation and pathway activation. Furthermore, CCL5 and CSF2 were identified as immune-related hub-genes and were found to be prognostic in a pan-cancer setting. Importantly, UC and ESCC patients with high expression of CCL5 and low expression of CSF2 responded better to ICIs. We demonstrated CCL5 and CSF2 as potential novel biomarkers for predicting the response to ICIs in patients with UC and ESCC. The predictive value of these biomarkers in other cancer types warrants further evaluation in future studies.
- 10 September 2024
- Published by Springer Nature in Cancer Cell International
- Vol. 24 (1) , 1-13
Open AccessPan-cancer analysis reveals CCL5/CSF2 as potential predictive biomarkers for immune checkpoint inhibitors
Currently, there are no optimal biomarkers available for distinguishing patients who will respond to immune checkpoint inhibitors (ICIs) therapies. Consequently, the exploration of novel biomarkers that can predict responsiveness to ICIs is crucial in the field of immunotherapy. We estimated the proportions of 22 immune cell components in 10 cancer types (6,128 tumors) using the CIBERSORT algorithm, and further classified patients based on their tumor immune cell proportions in a pan-cancer setting using k-means clustering. Differentially expressed immune genes between the patient subgroups were identified, and potential predictive biomarkers for ICIs were explored. Finally, the predictive value of the identified biomarkers was verified in patients with urothelial carcinoma (UC) and esophageal squamous cell carcinoma (ESCC) who received ICIs. Our study identified two subgroups of patients with distinct immune infiltrating phenotypes and differing clinical outcomes. The patient subgroup with improved outcomes displayed tumors enriched with genes related to immune response regulation and pathway activation. Furthermore, CCL5 and CSF2 were identified as immune-related hub-genes and were found to be prognostic in a pan-cancer setting. Importantly, UC and ESCC patients with high expression of CCL5 and low expression of CSF2 responded better to ICIs. We demonstrated CCL5 and CSF2 as potential novel biomarkers for predicting the response to ICIs in patients with UC and ESCC. The predictive value of these biomarkers in other cancer types warrants further evaluation in future studies.
- Open Access
- 9 April 2018
- Published by American Association for the Advancement of Science (AAAS) in Cancer Communications
- Vol. 38 (1) , 1-13
Protein‐coding genes combined with long noncoding RNA as a novel transcriptome molecular staging model to predict the survival of patients with esophageal squamous cell carcinoma
Background: Esophageal squamous cell carcinoma (ESCC) is the predominant subtype of esophageal carcinoma in China. This study was to develop a staging model to predict outcomes of patients with ESCC. Methods: Using Cox regression analysis, principal component analysis (PCA), partitioning clustering, Kaplan–Meier analysis, receiver operating characteristic (ROC) curve analysis, and classification and regression tree (CART) analysis, we mined the Gene Expression Omnibus database to determine the expression profiles of genes in 179 patients with ESCC from GSE63624 and GSE63622 dataset. Results: Univariate cox regression analysis of the GSE63624 dataset revealed that 2404 protein‐coding genes (PCGs) and 635 long non‐coding RNAs (lncRNAs) were associated with the survival of patients with ESCC. PCA categorized these PCGs and lncRNAs into three principal components (PCs), which were used to cluster the patients into three groups. ROC analysis demonstrated that the predictive ability of PCG‐lncRNA PCs when applied to new patients was better than that of the tumor‐node‐metastasis staging (area under ROC curve [AUC]: 0.69 vs. 0.65, P < 0.05). Accordingly, we constructed a molecular disaggregated model comprising one lncRNA and two PCGs, which we designated as the LSB staging model using CART analysis in the GSE63624 dataset. This LSB staging model classified the GSE63622 dataset of patients into three different groups, and its effectiveness was validated by analysis of another cohort of 105 patients. Conclusions: The LSB staging model has clinical significance for the prognosis prediction of patients with ESCC and may serve as a three‐gene staging microarray.
- 9 April 2018
- Published by American Association for the Advancement of Science (AAAS) in Cancer Communications
- Vol. 38 (1) , 1-13
Open AccessProtein‐coding genes combined with long noncoding RNA as a novel transcriptome molecular staging model to predict the survival of patients with esophageal squamous cell carcinoma
Background: Esophageal squamous cell carcinoma (ESCC) is the predominant subtype of esophageal carcinoma in China. This study was to develop a staging model to predict outcomes of patients with ESCC. Methods: Using Cox regression analysis, principal component analysis (PCA), partitioning clustering, Kaplan–Meier analysis, receiver operating characteristic (ROC) curve analysis, and classification and regression tree (CART) analysis, we mined the Gene Expression Omnibus database to determine the expression profiles of genes in 179 patients with ESCC from GSE63624 and GSE63622 dataset. Results: Univariate cox regression analysis of the GSE63624 dataset revealed that 2404 protein‐coding genes (PCGs) and 635 long non‐coding RNAs (lncRNAs) were associated with the survival of patients with ESCC. PCA categorized these PCGs and lncRNAs into three principal components (PCs), which were used to cluster the patients into three groups. ROC analysis demonstrated that the predictive ability of PCG‐lncRNA PCs when applied to new patients was better than that of the tumor‐node‐metastasis staging (area under ROC curve [AUC]: 0.69 vs. 0.65, P < 0.05). Accordingly, we constructed a molecular disaggregated model comprising one lncRNA and two PCGs, which we designated as the LSB staging model using CART analysis in the GSE63624 dataset. This LSB staging model classified the GSE63622 dataset of patients into three different groups, and its effectiveness was validated by analysis of another cohort of 105 patients. Conclusions: The LSB staging model has clinical significance for the prognosis prediction of patients with ESCC and may serve as a three‐gene staging microarray.
- 1 July 2012
- Published by Frontiers Media SA in Experimental Biology and Medicine
- Vol. 237 (7) , 860-866
Low expression of prolyl hydroxylase 2 is associated with tumor grade and poor prognosis in patients with colorectal cancer
Previous studies have indicated that prolyl hydroxylases (PHDs) function as tumor suppressors in human colorectal cancer (CRC), but their clinical and prognostic significance is uncertain. Expressions of PHD1, PHD2, PHD3 and hypoxia-inducible factor (HIF)-1 α were detected using immunohistochemistry in an independent CRC cohort of 93 specimens represented on a tissue microarray (TMA). PHD expression levels were correlated with clinicopathological features, patient survival and presumed corresponding HIF-1 α expression. Pearson χ2 test was used to compare clinicopathological features with protein expressions. Survival was estimated by Kaplan–Meier analysis. Cox regression analysis was performed for multivariate analysis of prognostic factors. Of the TMA, 47, 68 and 51 from 93 specimens had low expressions of PHD1, PHD2 and PHD3, respectively. HIF-1 α was positively expressed in 75 specimens. Low expression of PHD2 correlated with the high-grade group and a terrible overall survival ( P = 0.017 and P = 0.032). Patients who had early stage CRC with low PHD2 expression had a poorer survival ( P = 0.015), whereas patients with advanced-stage disease did not demonstrate such a difference ( P = 0.691). Besides, PHD2 was uncorrelated with HIF-1 α expression. The present study indicated that low expression of PHD2 in CRC predicts poor survival independent of HIF-1 α, specifically for patients who have early stage tumors.
- 1 July 2012
- Published by Frontiers Media SA in Experimental Biology and Medicine
- Vol. 237 (7) , 860-866
Low expression of prolyl hydroxylase 2 is associated with tumor grade and poor prognosis in patients with colorectal cancer
Previous studies have indicated that prolyl hydroxylases (PHDs) function as tumor suppressors in human colorectal cancer (CRC), but their clinical and prognostic significance is uncertain. Expressions of PHD1, PHD2, PHD3 and hypoxia-inducible factor (HIF)-1 α were detected using immunohistochemistry in an independent CRC cohort of 93 specimens represented on a tissue microarray (TMA). PHD expression levels were correlated with clinicopathological features, patient survival and presumed corresponding HIF-1 α expression. Pearson χ2 test was used to compare clinicopathological features with protein expressions. Survival was estimated by Kaplan–Meier analysis. Cox regression analysis was performed for multivariate analysis of prognostic factors. Of the TMA, 47, 68 and 51 from 93 specimens had low expressions of PHD1, PHD2 and PHD3, respectively. HIF-1 α was positively expressed in 75 specimens. Low expression of PHD2 correlated with the high-grade group and a terrible overall survival ( P = 0.017 and P = 0.032). Patients who had early stage CRC with low PHD2 expression had a poorer survival ( P = 0.015), whereas patients with advanced-stage disease did not demonstrate such a difference ( P = 0.691). Besides, PHD2 was uncorrelated with HIF-1 α expression. The present study indicated that low expression of PHD2 in CRC predicts poor survival independent of HIF-1 α, specifically for patients who have early stage tumors.